The Immune Monitoring in Kidney Transplant Recipients Could Predict Acute Rejection by a New Method: Flow Cytometric Microcarrier Assay
Zhankui Jin,Puxun Tian,Yi Cheng Lin,Wei Xue,Chenguang Ding,Ge Gao,T.-C. Mao,Min Xi,Wanxing Duan
DOI: https://doi.org/10.1097/00007890-201211271-02318
2012-01-01
Transplantation
Abstract:Introduction: In the field of solid organ transplantation, two different areas have developed: the use of biomarkers to predict allograft tolerance, and biomarkers for the prediction of allograft rejection. In the present study, we stimulate the peripheral blood lymphocytes (PBL) of kidney transplant recipients in vitro, and detect the expression of cell culture supernatant IL-2 and IL-6 or cell surface CD69 and CD71 by flow cytometric microcarrier assay (FCMA) to predict acute rejection. Methods: Forty kidney transplant recipients underwent kidney transplantation with living-related donor were selected as objects and divided into two groups that normal function (n=20) and acute rejection (n=20), and 10 healthy volunteers were selected as healthy control. Stimulate all objects PBL for 8 hours by phorbol myfismte acetate and ionomycin, and detect the expression of cell culture supernatant IL-2 and IL-6 or cell surface CD69 and CD71 by FCMA that polymer microspheres conjunct with probe and hybridize with ligand which waiting for test, and measure the fluorescence signal of probe by flow cytometry. The sensitivity and specificity of the method predict acute rejection by combine IL-2 and IL-6 or CD69 and CD71, which was analyzed by the curve of receiver operating characteristic (ROC). The study was approved by the local ethical committee. Results: The fluorescence intensity of IL-2 and IL-6 in healthy control were 108.82±65.30 and 983.97±896.88, respectively, and significant higher than group of normal function (26.11±11.31 and 105.36±61.60, respectively, P< 0.001, Figure 1 A/B). The fluorescence intensity of IL-2 and IL-6 in acute rejection (81.03±37.66 and 260.77±99.97, respectively.) significant higher than group of normal function (P< 0.01). The proportion of CD3+CD69+ and CD3+CD71+ T cell in group of healthy control were (37.28±20.43)% and (36.07±18.83)%, respectively, and significant higher than group of normal function [(7.66±2.88)% and (6.91±3.03)%, respectively, P< 0.001, Figure 1 C/D]. The proportion of CD3+CD69+ and CD3+CD71+ T cell in group of acute rejection [(23.27±15.37)% and (27.56±17.91)%, respectively] significant higher than group of normal function (P< 0.01). The sensitivity and specificity for predict acute rejection were 90% and 95%, respectively, when analyzed by the curve of ROC with combine IL-2 and IL-6. The sensitivity and specificity for predict acute rejection combines CD69 and CD71 were 95% and90%, respectively.[Figure 1 The results of FCMA (*P<0.05).]Conclusions: This study showed FCMA was a new method with high sensitivity and specificity. Monitoring the expression of cell culture supernatant IL-2 and IL-6 or cell surface CD69 and CD71 after stimulate the PBL of kidney transplant recipients in vitro by FCMA, which could predict acute rejection and provides an important reference for the early diagnosis of kidney rejection.